Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR et al.
Lancet 2024; 403: 2504-2519.
These two RCTs included over 1000 patients randomized to different doses of bimekizumab for up to 48 months. Responder rates were superior in those who received bimekizumab in both trials over placebo (I – 48 versus 29 per cent, P=0.006; II – 52 versus 32 per cent, P=0.0032). Side effects were infrequent.
Comment: At last, a meaningful treatment compared with surgery. Now for the direct comparison?
16 August 2024
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
